Silver Book Fact

Vaccines in development 2013

Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.

Pharmaceutical Researchers and Manufacturers of America. Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines. Washington, D.C.: PhRMA; 2013. http://phrma.org/medicines-in-development-for-vaccines-2013

Reference

Title
Medicines in Development: Vaccines–A report in the prevention and treatment of disease through vaccines
Publisher
PhRMA
Publication Date
2013
Authors
Pharmaceutical Researchers and Manufacturers of America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Cost of pneumonia vaccine
    Addition of PCV13 (13-valent pneumococcal conjugate vaccine) to previously recommended pneumococcal polysaccharide vaccine for immunocompromised adults cost $70,937 per quality adjusted life year compared to no vaccine.  
  • An antibiotic stewardship program saved $17 million over 8 years
    An antibiotic stewardship program saved a total of $17 million over 8 years, with antibiotic costs rising $1 million in the first year after discontinuation.  
  • Over 6 years, flu vaccine prevented ~13 million cases
    Over a 6-year period (2005 – 2011), the influenza vaccine prevented an estimated 13 million influenza cases–between 1.1 million and 5 million annually.  
  • Use of pneumonia vaccine in children reduced rates in adults age 65+
    Within a year of introduction of PCV7 (7-valent pneumococcal conjugate vaccine) for use in the U.S. in infants, children under 2 years, and high risk children ages 2 to 4;…  
  • Eradication of infectious diseases from vaccination
    Spanning more than 200 years of research and development, 10 infectious diseases have been at least 90 percent eradicated in the United States thanks to vaccines.